Novartis group Sandoz has launched two new biosimilars across the UK potentially expanding access to biologic treatments for a range of inflammatory conditions and blood cancers.
Novartis is poised to turn up the pressure on sales of Roche’s monoclonal antibody MabThera/Rituxan after EU regulators approved its cheaper biosimilar version of the mega blockbuster for use across blood malignancies and immunological diseases.